This one at least gives us a DME of 36.6, but it’s worth noting that DME is from the RQR VOR, so make sure your readout is coming from that and not the HRV VOR you might have been using as you ...

Vor Biopharma Inc. advanced stock charts by Barron's. View VOR historical stock data and compare to other stocks, and exchanges.

Check out our VOR stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.

Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with ...

Vor Bio plans to approach the U.S. Food & Drug Administration to discuss a pivotal trial design for trem-cel + Mylotarg by around year end. Continued progress with VCAR33 ALLO.

Vor Bio plans to approach the U.S. Food & Drug Administration to discuss a pivotal trial design for trem-cel + Mylotarg by around year end. Continued progress with VCAR33 ALLO.

BOSTON, September 06, 2024--PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies ...